Octagon Capital Advisors LP Taysha Gene Therapies, Inc. Transaction History
Octagon Capital Advisors LP
- $263 Million
- Q2 2025
A detailed history of Octagon Capital Advisors LP transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Octagon Capital Advisors LP holds 12,592,500 shares of TSHA stock, worth $36.6 Million. This represents 11.04% of its overall portfolio holdings.
Number of Shares
12,592,500
Previous 10,700,000
17.69%
Holding current value
$36.6 Million
Previous $14.9 Million
95.59%
% of portfolio
11.04%
Previous 4.95%
Shares
8 transactions
Others Institutions Holding TSHA
# of Institutions
154Shares Held
244MCall Options Held
107KPut Options Held
17K-
Rtw Investments, LP New York, NY25MShares$72.8 Million0.89% of portfolio
-
Ra Capital Management, L.P. Boston, MA23.6MShares$68.5 Million1.19% of portfolio
-
Avoro Capital Advisors LLC New York, NY21.7MShares$63.1 Million0.91% of portfolio
-
Morgan Stanley New York, NY16.9MShares$49.1 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY12.6MShares$36.6 Million0.0% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $141M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...